The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma

BACKGROUND. In the phase 3 trial ARIEL3, maintenance treatment with the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib provided clinical benefit versus placebo for patients with recurrent, platinum-sensitive ovarian cancer. Here, we evaluate the impact of age on the clinical utility of rucap...

Descripción completa

Detalles Bibliográficos
Autores principales: Colombo, Nicoletta, Oza, Amit M., Lorusso, Domenica, Aghajanian, Carol, Oaknin, Ana, Dean, Andrew, Weberpals, Johanne I., Clamp, Andrew R., Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W., Gancedo, Margarita Amenedo, Fong, Peter C., Goh, Jeffrey C., O'Malley, David M., Armstrong, Deborah K., Banerjee, Susana, García-Donas, Jesus, Swisher, Elizabeth M., Meunier, Juliette, Cameron, Terri, Maloney, Lara, Goble, Sandra, Bedel, Josh, Ledermann, Jonathan A., Coleman, Robert L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450972/
https://www.ncbi.nlm.nih.gov/pubmed/32861537
http://dx.doi.org/10.1016/j.ygyno.2020.05.045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450972/
https://www.ncbi.nlm.nih.gov/pubmed/32861537
http://dx.doi.org/10.1016/j.ygyno.2020.05.045

Ejemplares similares